

The *Salmonella* Type III Secretion Effector, *Salmonella* Leucine-rich Repeat Protein (SlrP), Targets the Human Chaperone ERdj3*

Received for publication, January 4, 2010, and in revised form, March 17, 2010. Published, JBC Papers in Press, March 24, 2010, DOI 10.1074/jbc.M110.100669

Joaquín Bernal-Bayard, Elena Cardenal-Muñoz¹, and Francisco Ramos-Morales²

From the Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Apartado 1095, 41080 Sevilla, Spain

Effectors of the type III secretion systems (T3SS) are key elements in the interaction between many Gram-negative pathogens and their hosts. SlrP is an effector that is translocated into the eukaryotic host cell through the two virulence-associated T3SS of *Salmonella enterica*. We found previously that this effector is an E3 ubiquitin ligase for mammalian thioredoxin. Here, we identified ERdj3, an endoplasmic reticulum luminal chaperone of the Hsp40/DnaJ family, as a new target for SlrP. Experiments with truncated forms of ERdj3 showed that domain II was essential for the interaction with SlrP. Confocal microscopy and subcellular fractionation demonstrated that, in transfected HeLa cells, SlrP was partially located in the endoplasmic reticulum. The presence of SlrP interfered with the binding of ERdj3 to a denatured substrate. Taken together, these data suggest that the role of SlrP in the interaction between *Salmonella* and the host cell is exerted through the modulation of the function of two independent targets: thioredoxin in the cytosol, and ERdj3 in the endoplasmic reticulum.

Salmonella is a genus of Gram-negative bacterial pathogens that belongs to the family Enterobacteriaceae. The genus includes thousands of serovars that can infect a wide variety of animals and produce different diseases, from gastroenteritis to typhoid fever, depending on the serovar and the host. Many Gram-negative pathogens rely on type III secretion systems (T3SS)³ for the delivery into the host cells of effector proteins that direct the different stages of the infection at the cellular level. *Salmonella enterica* possesses two distinct T3SS essential for virulence, encoded by genes located in the *Salmonella* pathogenicity islands 1 and 2 (SPI-1 and SPI-2), respectively. More than thirty T3SS effectors are known in *S. enterica* and some of them have been shown to manipulate key host functions,

including signal transduction, membrane traffic and pro-inflammatory immune responses (1, 2). However, the functions and cellular targets for many effectors are still unknown or incompletely understood.

SlrP (for *Salmonella* leucine-rich repeat protein) was identified by signature-tagged mutagenesis as a *S. enterica* serovar Typhimurium host range factor (3). This is one of the few effectors that can be secreted by the two virulence-related T3SS that are present in *S. enterica* (4). The gene *slrP* is located outside SPI-1 and SPI-2, in a 2.9-kb DNA region with features of horizontal acquisition. An *slrP*-null mutant has no difference in virulence with the wild-type strain when infecting calves but it is 6-fold attenuated for mouse virulence after oral infection (3). The predicted protein, SlrP, has a complete sequence of 765 amino acid residues that can be divided into several domains (5). The N-terminal 191 (and probably less) amino acid residues are sufficient for secretion and translocation into the eukaryotic host cells and show similarity to the N termini of *Salmonella* effectors SspH1, SspH2, SseI, SseJ, SifA, and SifB (4). The central domain (amino acids 176–564) contains several copies of a leucine-rich repeat signature, a protein motif frequently involved in protein-protein interactions (6, 7). The leucine-rich repeat domain is also found in other T3SS effectors including SspH1 and SspH2 from *S. enterica* serovar Typhimurium, YopM from *Yersinia* species and the IpaH family from *Shigella flexneri* (5). Finally, the C-terminal domain is also conserved in the effectors SspH1, SspH2, and the IpaH family. Recent studies uncovered E3 ubiquitin-ligase activities for effectors possessing this domain, including IpaH9.8, SspH1, and SspH2 (8, 9). Structural analysis showed that these effectors define a new class of ubiquitin ligases (8, 10, 11). In a previous work, we demonstrated that SlrP was able to interact with mammalian thioredoxin-1 (Trx). We also showed that SlrP is an E3 ubiquitin ligase that can use Trx as a substrate (12).

Below we show that ERdj3, a member of the Hsp40/DnaJ family of chaperones that is located in the endoplasmic reticulum in mammalian cells, is a second cellular target for SlrP. Our experiments suggest that this *Salmonella* effector can interfere with the function of ERdj3 by competing with the binding of unfolded client proteins.

EXPERIMENTAL PROCEDURES

Bacterial Strains, Yeast Strains, and Plasmids—Microbial strains and plasmids used in this study are listed and described in Table 1. Plasmid pIZ1729 is a derivative of pCS2 coding for ERdj3 with a C-terminal 3×HA tag. To construct this plasmid,

* This work was supported by Grants SAF2007-60738 from the Spanish Ministry of Science and Innovation and the European Regional Development Fund and P08-CVI-03487 from the Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía, Spain.

¹ Recipient of a predoctoral fellowship from the Junta de Andalucía.

² To whom correspondence should be addressed: Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Avda Reina Mercedes, 6, 41012 Sevilla, Spain. Tel.: 34-95-455-7107; Fax: 34-95-455-7104; E-mail: framos@us.es.

³ The abbreviations used are: T3SS, type three secretion system; SPI, *Salmonella* pathogenicity island; Trx, thioredoxin; Km, kanamycin; Amp, ampicillin; PBS, phosphate-buffered saline; PCV, packed cell volume; DB, DNA binding domain; AD, activation domain; NP40, Nonidet P40; HA, hemagglutinin; GST, glutathione S-transferase; SlrP, *Salmonella* leucine-rich repeat protein; cfu, colony-forming unit.

TABLE 1
Bacterial strains, yeast strains, and plasmids used in this study

Strain/plasmid	Relevant characteristics	Source/Ref.
<i>E. coli</i>		
DH5 α	<i>supE44</i> Δ <i>lacU169</i> (Δ 80 <i>lacZ</i> Δ M15) <i>hsdR17 recA1 endA1 gyrA96 thi-1 relA1</i>	(40)
BL21 (DE3)	F ⁻ <i>ompT gal dem lon hsdS_B</i> (<i>r_B⁻ m_B⁻</i> ; <i>E. coli</i> B strain), with DE3, a λ prophage carrying the T7 RNA <i>pol</i> gene	Stratagene
<i>S. enterica</i>		
14028	Wild type	ATCC
SV5193	14028 <i>slrP</i> ::3xFLAG, K _m ^r	(12)
<i>S. cerevisiae</i>		
AH109	<i>MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1^{UAS}-GAL1_{TATA}-HIS3, GAL2^{UAS}-GAL2_{TATA}-ADE2 URA3:: MEL1^{UAS}-MEL1_{TATA}-LacZ MEL1</i>	A. Holtz, unpublished
Y187	<i>MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, gal80Δ, met-, URA3:: GAL1^{UAS}-GAL1_{TATA}-LacZ MEL1</i>	(41)
Plasmids		
pcDNA3	Transient or stable transfection vector, Amp ^r	Invitrogen
pCS2+HA3	Transient transfection vector, Amp ^r	F. Romero
pGADT7	<i>GAL4</i> ₍₇₆₈₋₈₈₁₎ AD, <i>LEU2</i> , Amp ^r	Clontech
pGBT10	<i>GAL4</i> ₍₁₋₁₄₇₎ DB, <i>TRP1</i> , Amp ^r	Clontech
pGEX-4T-1	GST fusion vector, Amp ^r	Pharmacia
pGEX-4T-3	GST fusion vector, Amp ^r	Pharmacia
pIZ1623	pGEX-4T-3-SlrP	(12)
pIZ1627	pGBT10-SlrP	(12)
pIZ1706	pGADT7-ERdj3, clone obtained in the two-hybrid screen	This study
pIZ1708	pGEX-4T-1-ERdj3	This study
pIZ1720	pCS2-SlrP-3xFLAG	(12)
pIZ1725	pcDNA3-SlrP-3xFLAG	(12)
pIZ1729	pCS2-ERdj3-3xHA	This study
pIZ1780	pcDNA3-SlrP(C546A)-3xFLAG	(12)
pIZ1791	pGADT7-ERdj3(23-358)	This study
pIZ1792	pGADT7-ERdj3(88-358)	This study
pIZ1793	pGADT7-ERdj3(129-358)	This study
pIZ1794	pGADT7-ERdj3(160-358)	This study
pIZ1795	pGADT7-ERdj3(201-358)	This study
pIZ1796	pGADT7-ERdj3(251-358)	This study
pIZ1797	pGEX-4T-1-ERdj3(23-358)	This study
pIZ1798	pGEX-4T-1-ERdj3(88-358)	This study
pIZ1799	pGEX-4T-1-ERdj3(129-358)	This study
pIZ1800	pGEX-4T-1-ERdj3(160-358)	This study
pIZ1801	pGEX-4T-1-ERdj3(201-358)	This study
pIZ1802	pGEX-4T-1-ERdj3(251-358)	This study
pIZ1804	pGBT10-SlrP(C546A)	This study
pQE10-BiP		L. Hendershot

3 \times HA was amplified from plasmid pCS2+HA3 using primers 3HA5' and 3HA3', and ERdj3 cDNA was amplified from plasmid pIZ1706 using primers dnajbam5' and dnajxho3'. The first amplicon was digested with XhoI and XbaI and the second with BamHI and XhoI and both products were ligated together with vector pCS2+HA3 digested with BamHI and XbaI. All constructs were confirmed by sequencing.

DNA Amplification with the Polymerase Chain Reaction and Oligonucleotides—Amplification reactions were carried out in a Perkin Elmer Gene-Amp PCR System 2400 (PerkinElmer Life Sciences). The final volume of reactions was 50 μ l, and the final concentration of MgCl₂ was 1.5 mM. Reagents were used at the following concentrations: dNTPs, 200 μ M; primers, 1 μ M; and Taq polymerase (KAPA HiFi DNA polymerase, Kapa Biosystems), 1 unit per reaction. The thermal program included the following steps: (i) initial denaturation, 2 min at 94 $^{\circ}$ C; (ii) 25 cycles of denaturation (94 $^{\circ}$ C, 30 s), annealing (55 $^{\circ}$ C, 30 s), and extension (72 $^{\circ}$ C, 1 to 3 min); and (iii) final incubation at 72 $^{\circ}$ C for 7 min, to complete extension. Primers are listed in Table 2.

DNA Sequencing and Sequence Analysis—cDNA from the positive clone obtained in the two-hybrid screen, and PCR constructs were sequenced with an automated DNA sequencer (Stab Vida, Oeiras, Portugal). Sequence analysis was performed with molecular biology algorithms from the National Center

for Biotechnology Information (NCBI) and the European Bioinformatics Institute (EBI).

Bacterial Culture—The standard culture medium for *S. enterica* and *Escherichia coli* was LB broth. Solid LB contained agar 1.5% final concentration. Antibiotics were used at the following concentrations: kanamycin (Km), 50 μ g/ml; ampicillin (Amp), 100 μ g/ml.

Yeast Two-hybrid Methods—Plasmids were introduced into *Saccharomyces cerevisiae* strains using the lithium acetate procedure, as previously described (13). A human HeLa Matchmaker cDNA library (Clontech), prepared using the vector pGADT7 and pretransformed in *S. cerevisiae* strain Y187, was screened using yeast mating, according to the manufacturer instructions. Briefly, *S. cerevisiae* strain AH109 transformed with pIZ1627 was grown at 30 $^{\circ}$ C overnight with shaking in yeast drop-out medium lacking tryptophan. The culture was concentrated, mixed with 1 ml of the library in 45 ml of 2 \times YPDA, containing 2% yeast extract, 4% peptone, 4% glucose, and 0.006% adenine hemisulfate, and incubated at 30 $^{\circ}$ C overnight with gentle swirling. The mating mixture was plated in SD medium lacking leucine, tryptophan and histidine (Clontech). Plates were incubated at 30 $^{\circ}$ C for 8 days and then colonies were patched on the same medium and replica-plated on medium lacking tryptophan, leucine, histidine and adenine and in

TABLE 2
Oligonucleotides used in this study

Oligonucleotide/use	Sequence 5'-3' (restriction sites are underlined)
Construction of pIZ1708 dnaj5' dnaj3'	ATGCGA <u>ATTC</u> ATGGCTCCGCAGAACCTGAG TGACCT <u>CGAG</u> GTCCAATTTTATTCACTCTC
Construction of pIZ1729 3HA5' 3HA3' Dnajbam5' Dnajxho3'	ATCGCT <u>TCGAG</u> TACCCATACGATGTTCC TGCATCTAGATCAGCCAGCGTAGTCTGGTAC CTGAGGATCCACCATGGCTCCGCAGAACCTGAG TGACCT <u>CGAG</u> ATATCCTTGCAGTCCATTGTATAC
Construction of pIZ1791 and pIZ1797 dnaj23eco5' dnaj3'	CATGGA <u>ATTC</u> GGACGAGATTTCTATAAGATC as above
Construction of pIZ1792 and pIZ1798 dnaj88eco5' dnaj3'	CATGGA <u>ATTC</u> ACTTATGGTGAAGAAGGATTAAAAG as above
Construction of pIZ1793 and pIZ1799 dnaj129eco5' dnaj3'	CATGGA <u>ATTC</u> CCAAGAGGAAGTGATATTATTTG as above
Construction of pIZ1794 and pIZ1800 dnaj160eco5' dnaj3'	GATCGA <u>ATTC</u> GCAAGGCAGGCTCCTGGCAAAC as above
Construction of pIZ1795 and pIZ1801 dnaj201eco5' dnaj3'	CATGGA <u>ATTC</u> CTAGTGAATGAAGAACGAAC as above
Construction of pIZ1796 and pIZ1802 dnaj251eco5' dnaj3'	CATGGA <u>ATTC</u> TTTGAAGGAGAGGAGATGATTTG as above
Sequencing of pGADT7 derivatives T7	TAATACGACTCACTATAGGG
Sequencing of pGEX derivatives pgex5' pgex3'	GGGCTGGCAAGCCACGTTTGGTG CCGGGAGCTGCATGTGTGAGAGG

medium lacking leucine and tryptophan and supplemented with X- α -Gal, to check for the expression of the *ADE2* and the *MEL1* reporters, respectively. Positive clones were rescued, tested for specificity using empty pGBT10, and sequenced with primer T7.

Cell Culture, Lysis, and Transfection—HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. 2 mM L-glutamine, 100 units/ml penicillin, and 100 μ g/ml streptomycin were included in the culture medium. All cells were maintained in a 5% CO₂ humidified atmosphere at 37 °C. For cell lysis, 2 \times 10⁷ to 10⁸ cells per ml were incubated at 4 °C in Nonidet P-40 buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 μ g/ml pepstatin, and 1 μ g/ml leupeptin) for 20 min. The extract was centrifuged at 20,000 \times g for 20 min, and the supernatant was stored at -80 °C. For transient transfection assays, 2-5 \times 10⁶ HeLa cells/assay were resuspended in 200 μ l of 15 mM Hepes-buffered serum-containing medium, mixed with 50 μ l of 210 mM NaCl containing 5-10 μ g of plasmid DNA and electroporated using a BTX Electrocell Manipulator 600 set at 240 V, 720 Ω , 950 μ F. Cells were processed 24 h after electroporation.

Antibodies and Chemicals—Immobilized thyroglobulin conjugated to 4% cross-linked agarose beads, mouse monoclonal anti-FLAG M2, anti-FLAG M2 Cy3 conjugate, and rabbit polyclonal anti-ERdj3 antibodies were from Sigma. Protein A/G plus-agarose, protein A-agarose, and anti-Trx rabbit polyclonal antibody were from Santa Cruz Biotechnology. Anti-HA-peroxidase rat monoclonal antibody (clone 3F10) was from Roche

Diagnostics GmbH. Alexa Fluor® 488-labeled antibody HA.11 was from Covance. Peroxidase-linked anti-rabbit IgG was from GE Healthcare and peroxidase-linked anti-mouse IgG was from Bio-Rad.

GST and His₆ Fusion Proteins, Electrophoresis, and Immunoblot—Expression of the GST fusion proteins was induced by the addition of 1 mM isopropyl- β -D-thiogalactoside to *E. coli* BL21 (DE3) containing pGEX-4T-1, pGEX-4T-3, or their derivatives and the fusion proteins were isolated from bacterial lysates by affinity chromatography with glutathione-agarose beads (Sigma). 6His-BiP was produced after addition of 1 mM isopropyl- β -D-thiogalactoside to *E. coli* M15/pREP4 containing plasmid pQE10-BiP (a generous gift of Dr. L. Hendershot, University of Tennessee, Memphis), purified on Ni-NTA agarose beads (Qiagen) and eluted with 200 mM imidazole in binding buffer (100 mM KCl, 20 mM Tris, pH 7.0, 5 mM MgCl₂). For lysis, bacteria were sonicated in Nonidet P-40 buffer. For some binding experiments, lysates from *S. enterica* strain SV5193 were incubated for 2 h with fusion protein bound to glutathione-coupled agarose beads. The precipitates were washed six times in Nonidet P-40 buffer followed by SDS-PAGE (polyacrylamide gel electrophoresis). The gel was blotted onto a nitrocellulose membrane (Amersham Biosciences) and probed with primary antibodies. Goat anti-mouse horseradish peroxidase-conjugated antibodies (Bio-Rad) were used as secondary antibodies. Detection was via chemiluminescence procedures (Pierce).

Coimmunoprecipitation Experiments—For each experiment, a lysate from 5 \times 10⁶ HeLa cells cotransfected with plasmids pIZ1720 and pIZ1729, expressing SlrP-3 \times FLAG and ERdj3-

3xHA, respectively, and a lysate from 5×10^6 HeLa cells transfected with plasmid pIZ1729 only, were incubated with $4 \mu\text{l}$ of normal mouse IgG (Santa Cruz Biotechnology) for 1 h at 4°C , and with $20 \mu\text{l}$ of protein A/G plus-agarose beads (Santa Cruz Biotechnology) for 2 h at 4°C . After centrifugation the supernatants were incubated with $4 \mu\text{l}$ of monoclonal anti-FLAG antibodies for 2 h at 4°C , then overnight with $40 \mu\text{l}$ of protein A/G plus-agarose beads, and finally centrifuged. The beads were washed three times in Nonidet P-40 buffer containing 1% sodium deoxycholate and 300 mM NaCl, twice in Nonidet P-40 buffer containing 1% sodium deoxycholate and 150 mM NaCl, and once in Nonidet P-40 buffer containing 1% sodium deoxycholate and 10 mM NaCl. Proteins were eluted and dissolved into Laemmli sample buffer (50 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 0.0005% bromphenol blue) containing 5% β -mercaptoethanol, incubated at 95°C for 5 min and subjected to SDS-PAGE. Proteins were transferred to a nitrocellulose filter and probed with anti-FLAG (Sigma) and anti-HA-peroxidase (clone 3F10, Roche).

Immunofluorescence and Confocal Microscopy—Direct immunofluorescence was performed with cells cultured on permax Lab-Tek® chamber slides (Nunc). Cells were fixed for 6 min in ice-cold methanol and rinsed thoroughly with phosphate-buffered saline (PBS) and PBS containing 0.1% Tween 20. Cells were incubated for 30 min at room temperature with 3% bovine serum albumin (BSA) in PBS-Tween and 1 h in antibody diluted in PBS-Tween-BSA. Antibodies were anti-FLAG M2 monoclonal antibody-Cy3 conjugate (Sigma) and anti-HA Alexa Fluor® 488 labeled antibody (Covance) diluted 1:1000. After immunostaining, cells were rinsed with PBS and mounted for microscopy using ProLong Gold (Invitrogen). All images were acquired using a Leica TCS SP2 confocal microscope.

Microsomal Preparation—HeLa cells (3×10^8) were detached with trypsin, washed with PBS, and centrifuged to calculate the packed cell volume (PCV). Cells were suspended in a volume of hypotonic extraction buffer (10 mM HEPES, pH 7.8, 25 mM potassium chloride, and 1 mM EGTA) equivalent to 3 times the PCV and incubate for 20 min at 4°C to allow the cells to swell. The cells were centrifuged at $600 \times g$ for 5 min, the supernatant was removed by aspiration, and the new PCV was measured. The cells were suspended in a volume of isotonic extraction buffer (10 mM HEPES, pH 7.8, 250 mM sucrose, 25 mM potassium chloride, and 1 mM EGTA) equivalent to 2 times the new PCV and broken in a 7 ml homogenizer (Kontes) with 10 strokes. The homogenate was centrifuged at $1000 \times g$ for 10 min at 4°C and the supernatant was transferred to another centrifuge tube. After a centrifugation at $12,000 \times g$ for 15 min at 4°C , the supernatant fraction, which is the postmitochondrial fraction, was centrifuged for 60 min at $100,000 \times g$ at 4°C . The supernatant is the cytosol fraction. The pellet from this last centrifugation, which is the microsomal fraction, was suspended in isotonic extraction buffer.

ERdj3-BiP Binding Assays—Binding assays were performed as previously described (14) with appropriate modifications. Briefly, GST-ERdj3-1 (with amino acids 23–765 of ERdj3), GST-ERdj3-3 (with amino acids 129–765 of ERdj3) and GST-SlrP were purified on glutathione-agarose beads as described above. $50 \mu\text{g}$ of immobilized GST-ERdj3-1 or GST-ERdj3-3

were incubated with $50 \mu\text{g}$ of soluble His₆-BiP, in the presence or absence of 1 mM ATP and $50 \mu\text{g}$ of GST-SlrP, in a total volume of $500 \mu\text{l}$ of binding buffer. After incubating at 4°C , for 2 h, in a rotating platform, the beads were washed five times with 1 ml of binding buffer. Bound proteins were resolved by SDS-PAGE and detected by Coomassie Blue staining.

ATPase Assays—*In vitro* assays were performed as previously described (14) with some modifications to adapt the protocol to a non-radioactive procedure, as follows. GST-SlrP, GST-ERdj3-1, GST, and His₆-BiP were purified as described above and dialyzed overnight into ATPase assay buffer (50 mM HEPES, pH 6.8, 50 mM NaCl, 2 mM MgCl₂). Assays were performed in a final volume of $100 \mu\text{l}$ consisting of ATPase buffer, with 20 mM KCl, and $20 \mu\text{M}$ ATP. Reactions contained $1 \mu\text{g}$ of His₆-BiP and different combinations of GST, GST-ERdj3, and GST-SlrP ($2.5 \mu\text{g}$ each). Comparison was made with a reaction containing neither His₆-BiP nor a GST-containing protein. After incubating at 25°C for 75 min, the concentration of phosphate released in the reactions was measured using the Malachite Green Phosphate Assay Kit (Cayman Chemical) according to the manufacturer's instructions.

Thyroglobulin Binding Assay—A method previously described (15) was used with some modifications. Immobilized thyroglobulin was denatured (dTg) in 6 M urea, 1 M β -mercaptoethanol, for 40 min at room temperature with rocking. Beads were washed and equilibrated in Nonidet P-40 buffer. Aliquots of dTg were incubated with total HeLa cell lysates for 3 h at 4°C with rocking. After five washes with 1 ml of Nonidet P-40 buffer, proteins bound to beads were analyzed by SDS-PAGE (10%) and immunoblot.

RESULTS

Salmonella SlrP Interacts with Human ERdj3 in the Yeast Two-hybrid System—In an attempt to identify mammalian partners for *Salmonella* T3SS effector SlrP, a screen of a HeLa cDNA library was performed using SlrP as bait in the yeast two-hybrid system (12). The cDNA insert from one of the clones obtained in medium lacking histidine, used to select for the interactions, contained the entire coding sequence for human ERdj3 (Fig. 1A). Colonies from this clone were also able to grow in the absence of adenine and were blue in the presence of X- α -Gal, indicating that they expressed three different reporter genes used in this system: *HIS3*, *ADE2*, and *MEL1*. The specificity of the SlrP/ERdj3 interaction was confirmed by the lack of reporter gene activation when the empty vector (pGBT10) was used instead of the SlrP plasmid (Fig. 1B).

Domain II of ERdj3 Is Essential for Association with SlrP—ERdj3 is a molecular chaperone of the Hsp40/DnaJ family. It contains an N-terminal signal peptide, necessary for its localization in the endoplasmic reticulum. The signal peptide is absent in the mature form of the protein (14). ERdj3 also possesses a J domain that binds to BiP, the mammalian endoplasmic reticulum Hsp70/DnaK chaperone, a Gly/Phe-rich domain, and a C-terminal substrate binding fragment. The C-terminal fragment contains three domains called I, II, and III. Domain I is interrupted by the Cys-rich domain II, which is a hallmark of type I DnaJ proteins (Fig. 1A). On the basis of the previously defined domain boundaries (16), we made sequen-

SlrP Interacts with ERdj3




FIGURE 1. Interaction of *Salmonella* SlrP with human ERdj3 in the yeast two-hybrid system. *A*, diagram of the domains of full-length and deleted versions (1–6) of ERdj3. The domains of ERdj3 are indicated as: *J*, *J* domain; *G/F*, glycine-, and phenylalanine-rich domain; *Ia*, domain Ia; *II*, domain II; *Ib*, domain Ib; *III*, domain III. *B*, diploids were obtained by conjugation between strain AH109, containing derivatives of pGBT10 (DB-SlrP), and strain Y187, containing derivatives of pGADT7 (AD-ERdj3), as indicated. The interaction between the two hybrid proteins is shown by the growth in the absence of histidine and adenine. *DB*, fusion with the DNA-binding domain of Gal4; *AD*, fusion with the activation domain of Gal4; *wt*, wild-type SlrP; *C546A*, C546A mutant of SlrP; 1 to 6 correspond to ERdj3 subclones represented in *A*; –, empty vectors.




FIGURE 2. Interaction of ERdj3 and SlrP *in vitro*. *A*, *in vitro* binding of SlrP-3×FLAG to GST-ERdj3. Expression of GST and GST-ERdj3 proteins was induced with isopropyl-1-thio-β-D-galactopyranoside, and proteins were isolated from bacterial lysates by affinity chromatography with glutathione-agarose beads. 4 μg of each GST protein were incubated with lysates from 10⁹ cfu of *S. enterica* serovar Typhimurium strain SV5193 (14028 *slrP*::3×FLAG) prepared in Nonidet P-40 lysis buffer. After washing, proteins eluted in sample buffer were resolved in 12% SDS-PAGE, blotted on nitrocellulose filters, and developed with monoclonal anti-FLAG antibody. Lysate from 10⁸ cfu of the same strain is also included for reference. *B*, domain II of ERdj3 is essential for interaction with SlrP. Deleted derivatives of ERdj3 1–6 (see Fig. 1*A*) were expressed in fusion with GST and used for binding experiments with lysates from 10⁹ cfu of *Salmonella* strain SV5193 as in *A*. *M*, molecular mass markers; visible bands correspond to 150, 100, 75, 50, 37, and 25 kDa.

tial deletion mutants, from ERdj3–1 to ERdj3–6. Construction 1 corresponds to the mature form of the protein, without signal peptide. Construction 6 corresponds to domain III plus the 30 C-terminal amino acids (see Fig. 1*A* for additional details). Each of the ERdj3 constructs was tested in the two-hybrid system in yeasts for interaction with SlrP. Empty vectors were used as controls (Fig. 1*B*, *third column* and *seventh row*). Growth in the absence of histidine and adenine showed that all constructs, except 5 and 6, were able to interact with SlrP in the two-hybrid

system (Fig. 1*B*, *first column*). Since mutants 5 and 6 lack domain II, these results indicate that this domain of ERdj3 is essential for the association with SlrP. In addition, a non-catalytic mutant form of SlrP in which Cys-546 was changed to Ala exhibited the same pattern of interaction as the wild type (Fig. 1*B*, *second column*; see “Discussion”).

Interaction of SlrP and ERdj3 Is Confirmed by Pull-down Experiments—To confirm the results obtained with the two-hybrid approach, the prokaryotic GST expression system was used to produce recombinant ERdj3 as GST fusion protein. GST-ERdj3 purified and immobilized on glutathione-agarose beads was incubated with a lysate of strain SV5193, an *S. enterica* serovar Typhimurium strain that codes for a 3×FLAG-tagged form of SlrP (12). After washing, the complexes

were analyzed by immunoblot with anti-FLAG monoclonal antibodies. As seen in Fig. 2*A*, SlrP-3×FLAG interacted with GST-ERdj3 but not with GST, showing that the interaction was specific. A similar analysis was carried out with ERdj3 deletion derivatives 1 to 6 expressed in the form of GST fusion proteins. Constructs 1–4, but not 5 and 6, were able to interact with SlrP-3×FLAG (Fig. 2*B*, *upper panel*). The amount and size of the chimeric proteins used in the binding experiments was assessed by reversible staining of the nitrocellulose filter with Ponceau S red (Fig. 2*B*, *lower panel*). Taken together, these findings confirm that ERdj3 associates with SlrP and that domain II of ERdj3 is essential for this interaction.

SlrP and ERdj3 Interact in HeLa Cells—To investigate if this interaction could exist *in vivo*, in the host cell, coimmunoprecipitation experiments were carried out. HeLa cells were co-transfected with a plasmid coding for SlrP-3×FLAG and another plasmid coding for ERdj3–3×HA. Lysates were prepared, anti-FLAG antibodies were used for immunoprecipitation, and the presence of ERdj3 in the immunoprecipitation complexes was investigated by immunoblot with anti-HA antibodies (Fig. 3). ERdj3–3×HA was clearly detected in the anti-FLAG immunoprecipitates. As a control of specificity, the same experiment was performed with a lysate from HeLa cells transfected with the plasmid coding for ERdj3–3×HA only. In this case the tagged ERdj3 protein was not detectable in the immunoprecipitates. These findings suggest that the complex SlrP/ERdj3 may exist in host cells, confirming and extending the results obtained with the two-hybrid system and GST fusion proteins.

SlrP Is Partially Located in the Endoplasmic Reticulum—SlrP has been described as evenly distributed in the cytoplasm when expressed in mammalian cells (17). On the other hand, ERdj3, a member of the Hsp40 family of cochaperones, is exclusively located in the endoplasmic reticulum (18). The interaction




FIGURE 3. Coimmunoprecipitation of SlrP and human ERdj3. HeLa cells were transiently co-transfected with 4 μ g of two derivatives of plasmid pCS2, one expressing SlrP-3 \times FLAG, and the other ERdj3-3 \times HA (lane 1), or transfected with the plasmid expressing ERdj3-3 \times HA only (lane 2). Nonidet P-40 lysates from 5×10^6 transfected cells were subjected to immunoprecipitation (IP, right panels) with anti-FLAG monoclonal antibodies and, after the stringent washings described under "Experimental Procedures," resolved by 10% SDS-PAGE, transferred to nitrocellulose membranes, and developed with monoclonal anti-FLAG for the upper part of the membrane, and monoclonal anti-HA for the lower part. Lysates from 5×10^5 transfected cells are shown in the left panels.




FIGURE 4. Colocalization of SlrP and ERdj3 in HeLa cells. *A*, microscopic analysis. HeLa cells transiently transfected with plasmids expressing SlrP-3 \times FLAG and ERdj3-3 \times HA were observed in a laser-scanning confocal microscope after permeabilization and staining with Alexa Fluor[®] 488 labeled anti-HA (green, upper panel) and Cy3-conjugated anti-FLAG (red, center panel). Superposition of the two labelings is shown in the lower panel. Yellowish staining indicates colocalization of SlrP and ERdj3 in the endoplasmic reticulum. Scale bar, 10 μ m. *B*, detection of SlrP in the endoplasmic reticulum of HeLa-transfected cells. Total lysate (left panels) and microsomal fraction (right panels) from 10^7 HeLa cells stably expressing SlrP-3 \times FLAG were submitted to 15% SDS-PAGE, transferred to nitrocellulose membrane, and then probed with anti-FLAG monoclonal antibody to detect SlrP. The filter was also incubated with anti-ERdj3 and anti-Trx polyclonal antibodies to detect endogenous ERdj3, and endogenous Trx (a cytosolic and partially nuclear protein), respectively, as a control of the purity of the microsomal fraction. *C*, comparison of the migration of SlrP present in cytosolic and microsomal fractions of transfected HeLa cells. A cytosolic fraction (10^6 cells) and a microsomal fraction (10^7 cells) obtained from HeLa cells stably expressing SlrP-3 \times FLAG were submitted to 10% SDS-PAGE, transferred to nitrocellulose membrane and then probed with anti-FLAG monoclonal antibody to detect SlrP.

described above could only take place *in vivo* if SlrP is, at least partially, located in the endoplasmic reticulum. This reasoning prompted us to investigate the subcellular localization of SlrP in HeLa cells. First, the localization of SlrP and ERdj3 was studied in cells transfected with the plasmids coding for SlrP-3 \times FLAG and ERdj3-3 \times HA using immunofluorescence and confocal microscopy. As seen in Fig. 4A, although SlrP is broadly distributed in the cytoplasm, colocalization with ERdj3 proteins is observed in the endoplasmic reticulum. Next, the localization of SlrP-3 \times FLAG was examined by subcellular fractionation. Microsome fraction was prepared from HeLa cells stably transfected with the plasmid coding for SlrP-3 \times FLAG, and the presence of SlrP-3 \times FLAG and ERdj3 in this fraction was assessed by immunoblot with anti-FLAG and anti-ERdj3 antibodies,

respectively. Comparison with total extract reveals that ERdj3 is essentially located in microsomes, as expected, and that a significant part of the SlrP protein is in the same fraction (Fig. 4B). The absence of thioredoxin, a cytosolic, and nuclear protein, provided the control for the purity of the microsome fraction. Localization in the endoplasmic reticulum usually requires an N-terminal signal peptide that is cleaved upon translocation into this cellular compartment (19). The presence of such a signal in SlrP would produce two different molecular weight forms, one in the cytosol and the other in the endoplasmic reticulum. To assess this possibility we compared cytosolic and microsomal fractions of HeLa cells stably expressing SlrP-3 \times FLAG by Western blot with anti-FLAG antibodies (Fig. 4C). Proteins were separated in a 10% polyacrylamide gel instead of the 15% gel used in Fig. 4B to get a better resolution of the SlrP forms. Fig. 4C clearly shows a higher molecular weight form of SlrP in the cytosolic fraction and a lower molecular weight form in the microsomal fraction, which is in agreement with our hypothesis.

SlrP Interferes with the Function of ERdj3 in a Ubiquitination-independent Manner—ERdj3 interacts with BiP and stimulates its ATPase activity (14). In addition ERdj3 binds directly to unfolded substrates (16). We hypothesized that the interaction between SlrP and ERdj3 could in some way alter the function of the host protein. To test our hypothesis, first we examined the binding of ERdj3 to BiP using GST-ERdj3 and His₆-BiP, as previously described (14). 6His-BiP was able to bind to GST-ERdj3-1 (the mature form of the protein), but not to GST-ERdj3-3 (which lacks the J domain), in an ATP-dependent manner, as expected, but the presence of GST-SlrP in the binding experiments did not alter the results (Fig. 5A).

Next, we studied the effect of SlrP on the ability of ERdj3 to stimulate the ATPase activity of BiP. *In vitro* reactions were performed with 6His-BiP in the absence or presence of GST-ERdj3-1 and GST-SlrP, and the concentration of released phosphate was measured as described under "Experimental Procedures." As seen in Fig. 5B some phosphate was detected in the absence of BiP, probably because of spontaneous release in the ATP preparation. The presence of BiP increased the concentration of released phosphate and ERdj3 was able to stimulate the ATPase activity of BiP to the same level irrespective of the presence of SlrP.

Finally, we assessed the binding of ERdj3 to immobilized, denatured thyroglobulin (dTg), a known substrate for this chaperone (15), in the presence or absence of SlrP. Fig. 5C shows that, when a total extract of HeLa cells transfected with ERdj3-3 \times HA was incubated with immobilized dTg, binding of a fraction of ERdj3-3 \times HA was detected, as expected. There was no significant binding to native protein A immobilized on agarose, which was used as a negative control. Preincubation with an extract from HeLa cells expressing SlrP-3 \times FLAG significantly reduced the binding of ERdj3 to dTg (Fig. 5D). Similar results were obtained when the experiment was repeated using an extract of HeLa cells expressing a mutant form of SlrP in which Ala substituted for Cys-546, a residue necessary for full ubiquitin ligase activity (12). No effect was observed when preincubation was carried out with an extract of non-transfected HeLa cells, used as control. The results presented in this section

SlrP Interacts with ERdj3




FIGURE 5. Effect of SlrP on ERdj3 function. *A*, binding of ERdj3 to BiP. 50 μg of GST-ERdj3-1 (amino acids 23–358) or GST-ERdj3-3 (amino acids 129–358) immobilized in glutathione-agarose beads were incubated with 50 μg of His₆-BiP in the presence or absence of 1 mM ATP and 50 μg of GST-SlrP as indicated. After incubating at 4 °C for 2 h, the beads were washed several times with binding buffer, and bound proteins were released by boiling for 5 min in sample buffer and subjected to 10% SDS-PAGE. Proteins were detected by Coomassie Blue staining. One stained gel is shown together with a graphical representation (below) of means ± S.D., from two independent experiments, of the quantification of bands of His₆-BiP. *B*, stimulation of BiP ATPase activity by ERdj3. ATPase assays were performed with either no additions (*None*), 1 μg of His₆-BiP plus 2.5 μg of GST (*BiP*), 1 μg of His₆-BiP plus 2.5 μg of GST-ERdj3-1 plus 2.5 μg of GST (*BiP+ERdj3*), or 1 μg of His₆-BiP plus 2.5 μg of GST-ERdj3-1 plus 2.5 μg GST-SlrP (*BiP+ERdj3+SlrP*). The amount of released phosphate was determined after incubation at 25 °C for 75 min with a non-radioactive procedure (see “Experimental Procedures”). Values are the mean of three separate experiments with an error bar representing S.D. *C*, binding of ERdj3 to dTg. Lysates from HeLa cells transiently expressing ERdj3-3×HA were mixed with lysates from untransfected cells (*UTC*) or with lysates transfected with SlrP or SlrPCys546Ala (*C546A*), as indicated, and then incubated with dTg or native protein A immobilized on agarose beads. After several washes with Nonidet P-40 buffer, proteins bound to the beads (*Bi*) were released by boiling in sample buffer, separated by using 10% SDS-PAGE and immunoblotted with anti-HA monoclonal antibodies. Part of the initial flow-through (*F*) obtained after the incubations was also included. *D*, image quantification of the relative amount of ERdj3 bound to immobilized dTg. The results are the mean ± S.D. of three independent experiments. The highest level was set to 100 for each experiment.

suggest that the interaction of SlrP with ERdj3 could have a functional significance decreasing the ability of this chaperone to bind denatured substrates, and that this effect is independent of the E3 ubiquitin ligase activity of SlrP.

DISCUSSION

Identification of eukaryotic targets for individual T3SS effectors is an essential step in the understanding of the function of these virulence factors. In a previous work, we identified human Trx as a partner for SlrP (12). Now, we have identified a second cellular target, ERdj3. The interaction of SlrP with this protein has been confirmed through three independent approaches: *in vivo* interaction in yeast with the two-hybrid system (Fig. 1), pull-down experiments with GST fusion proteins produced in bacteria (Fig. 2), and coimmunoprecipitation from transfected human epithelial HeLa cells (Fig. 3).

ERdj3/HEDJ is a protein of the Hsp40/DnaJ family localized in the endoplasmic reticulum (14). ERdj3 is an important chaperone/co-chaperone that associates with a number of unfolded proteins that are substrates of the Hsp70/DnaK family member

GRP78/BiP (20–23). In addition, ERdj3 is able to bind client proteins directly and independently of BiP (16).

The interaction of SlrP with an endoplasmic reticulum protein prompted us to investigate its subcellular localization. A previous report, using conventional immunofluorescence microscopy, showed that HA-tagged SlrP was present in the cytoplasm and excluded from the nucleus of transiently transfected Raw-TT10 and CHO-K1 cells (17). Our confocal microscopy experiments confirm that SlrP is evenly distributed in the cytoplasm of HeLa cells but also show a significant overlap with ERdj3 (Fig. 4A). The partial localization of SlrP in the endoplasmic reticulum was confirmed by analysis of a microsomal fraction obtained from transfected HeLa cells. Quantitative comparison of the bands in Fig. 4B indicates that at least 10% of SlrP is in the microsomal fraction. When trying to identify a signal sequence in SlrP that could direct translocation into the endoplasmic reticulum with the program SigPred (J. R. Bradford, University of Leeds) a putative signal (ISAFFSSE-HQVEA) was detected. However when other programs, including SignalP (24), were used, no signal was predicted. The presence of an imperfect signal sequence could explain the partial localization of

SlrP in the endoplasmic reticulum shown by our experiments. In fact, different signal sequences have different efficiencies in initiating translocation (25, 26), which could explain previous examples of proteins residing in multiple compartments (27). In the case of SlrP, this would allow interaction with two different cellular targets, Trx and ERdj3, which are located in different cellular compartments, in a non-competitive way. The results in Fig. 4C, showing different molecular weights for the fractions of SlrP present in the endoplasmic reticulum and in the cytosol, suggest that there is in fact a signal peptide in SlrP that is cleaved during translocation into the endoplasmic reticulum.

Members of the DnaJ family have been classified as type I, II, or III. Type I proteins contain three regions in common: a J domain, a Gly/Phe-rich domain, and a Cys-rich domain of four CXXCXG. Type II proteins have the J and Gly/Phe domains, whereas type III proteins have only the J domain in common (28, 29). Although ERdj3 contains the typical J and Gly/Phe domains, it has an atypical Cys-rich domain with one CXC and one CXXC motifs, whose presence and redox state contribute

to substrate interactions (15). ERdj3 is similar to the yeast DnaJ protein Ydj1(30, 31). Structural studies on this protein established that its C terminus can be divided into three domains, called domain I, II, and III that are also found in ERdj3. Domain I and domain II of ERdj3 are essential for substrate binding (16). Our experiments with truncated forms of ERdj3 (Figs. 1 and 2) indicated that domain II, but not domain I, of ERdj3, is essential for the interaction with SlrP. These results suggest that SlrP is not just acting as a denatured substrate and that the ERdj3/SlrP interaction is specific. The absence of domains J and Gly/Phe-rich, did not affect the interaction. In agreement with these results, interaction of ERdj3 with BiP and stimulation of its ATPase activity, which are mediated by the J domain, were not affected by the presence of SlrP (Fig. 5, A and B). However, SlrP significantly reduced interaction of ERdj3 with a denatured substrate (thyroglobulin) (Fig. 5, C and D). This latter result means that the interaction of this *Salmonella* effector with ERdj3 can have important functional consequences: since domain II is essential both for the interaction with SlrP and with denatured client proteins, competition for this domain in ERdj3 could lead to accumulation of unfolded proteins in the endoplasmic reticulum. This accumulation could initiate activation of the unfolded protein response. Finally, if the protein folding defect is not resolved, chronic activation of the unfolded protein responses can eventually induce apoptosis (reviewed in Ref. 32). *Salmonella* infections of cultured cells usually lead, in the short or the long term, to apoptosis or other forms of cell death (33–35). In addition we have recently shown that expression of SlrP in HeLa cells makes them more prone to death (12). It is tempting to speculate that the interaction of SlrP with ERdj3, by competing with substrates and promoting accumulation of unfolded proteins in the endoplasmic reticulum, could contribute to cell death as observed in HeLa cells transfected with a plasmid expressing SlrP or infected with *Salmonella*.

It has been previously shown that *S. enterica* serovar Typhimurium inhibits antigen presentation by dendritic cells and antigen-dependent T-cell proliferation, and that the SPI2-encoded T3SS is involved in this inhibition (36, 37). Interestingly, SlrP is one of the effectors of this secretion system that are involved in the interference with antigen presentation (38). The interaction of SlrP with ERdj3 and their competition for unfolded substrates could also have a connection with these findings, because endoplasmic reticulum stress impairs major histocompatibility complex class I-peptide presentation (39).

SlrP is an E3 ubiquitin ligase that can use Trx as a substrate (12). The interaction demonstrated in this study suggests that ERdj3 might be another substrate for SlrP-dependent ubiquitination. In fact, ubiquitinated forms of ERdj3 are detected after *in vitro* reactions using SlrP as an E3 ubiquitin ligase (data not shown). However, *in vivo* ubiquitination of ERdj3 is unlikely because this is an endoplasmic reticulum luminal protein and ubiquitination has not been described in this cell compartment. On these grounds, we favor the idea that the role of SlrP in the endoplasmic reticulum is unrelated to its ligase activity. This view is reinforced by the results obtained with the ubiquitin ligase inactive mutant of SlrP in which Cys-546 has been changed to Ala: this mutant is as able as the wild-type SlrP to interact with ERdj3 (Fig. 1) and to interfere with denatured

substrate interaction (Fig. 5). In addition, this mutant is also able to increase spontaneous cell death in transfected HeLa cells on reaching confluence, although not at the same level as the wild type (12). A role unrelated to its ubiquitin ligase activity has also been suggested for the C-terminal domain of SspH2, a T3SS *Salmonella* effector that has similarities with SlrP (8).

Taken together, the data shown above and our previous results studying the interaction of SlrP with Trx (12), our present working model suggests that, after being translocated into the host cell through both the SPI-1- and the SPI-2-dependent T3SS of *Salmonella*, SlrP promotes death of the cell by two complementary mechanisms: (i) interaction with Trx in the cytosol leads to ubiquitination of this target and causes a decrease in its redox activity; (ii) interaction with ERdj3 in the endoplasmic reticulum interferes, in a ubiquitin ligase independent way, with the function of this chaperone, causing the accumulation of unfolded proteins in this cell compartment. Additionally, this latter effect could explain the SlrP-dependent inhibition of antigen presentation by dendritic cells.

In summary, the present study demonstrate the existence of a second cell host target, ERdj3, for the *Salmonella* T3SS effector SlrP, and support a model in which SlrP has a role in the endoplasmic reticulum that could have important physiological consequences for the infected cells. The identification of the targets of T3SS effectors and the elucidation of the molecular details of the interactions, as well as of their functional results, are important contributions to the understanding of the mechanisms that these fascinating molecules use to manipulate the host eukaryotic cells behavior.

Acknowledgments—We thank F. Romero (Universidad de Sevilla, Spain) and L. Hendershot (St. Jude Children's Research Hospital, Memphis, TN) for kindly providing some plasmids, F. Romero and J. Casadesús (Universidad de Sevilla, Spain) for critical reading of the manuscript, and V. Goder (Universidad de Sevilla, Spain) for helpful discussions.

REFERENCES

1. Haraga, A., Ohlson, M. B., and Miller, S. I. (2008) *Nat. Rev. Microbiol.* **6**, 53–66
2. McGhie, E. J., Brawn, L. C., Hume, P. J., Humphreys, D., and Koronakis, V. (2009) *Curr. Opin. Microbiol.* **12**, 117–124
3. Tsolis, R. M., Townsend, S. M., Miao, E. A., Miller, S. I., Ficht, T. A., Adams, L. G., and Bäuml, A. J. (1999) *Infect. Immun.* **67**, 6385–6393
4. Miao, E. A., and Miller, S. I. (2000) *Proc. Natl. Acad. Sci. U.S.A.* **97**, 7539–7544
5. Miao, E. A., Scherer, C. A., Tsolis, R. M., Kingsley, R. A., Adams, L. G., Bäuml, A. J., and Miller, S. I. (1999) *Mol. Microbiol.* **34**, 850–864
6. Bella, J., Hindle, K. L., McEwan, P. A., and Lovell, S. C. (2008) *Cell Mol. Life Sci.* **65**, 2307–2333
7. Kobe, B., and Kajava, A. V. (2001) *Curr. Opin. Struct. Biol.* **11**, 725–732
8. Quezada, C. M., Hicks, S. W., Galán, J. E., and Stebbins, C. E. (2009) *Proc. Natl. Acad. Sci. U.S.A.* **106**, 4864–4869
9. Rohde, J. R., Breitkreutz, A., Chenal, A., Sansonetti, P. J., and Parsot, C. (2007) *Cell Host Microbe* **1**, 77–83
10. Singer, A. U., Rohde, J. R., Lam, R., Skarina, T., Kagan, O., Dileo, R., Chirgadze, N. Y., Cuff, M. E., Joachimiak, A., Tyers, M., Sansonetti, P. J., Parsot, C., and Savchenko, A. (2008) *Nat. Struct. Mol. Biol.* **15**, 1293–1301
11. Zhu, Y., Li, H., Hu, L., Wang, J., Zhou, Y., Pang, Z., Liu, L., and Shao, F. (2008) *Nat. Struct. Mol. Biol.* **15**, 1302–1308
12. Bernal-Bayard, J., and Ramos-Morales, F. (2009) *J. Biol. Chem.* **284**,

27587–27595

13. Sherman, F., Fink, G. R., and Hicks, J. B. (1986) *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
14. Yu, M., Haslam, R. H., and Haslam, D. B. (2000) *J. Biol. Chem.* **275**, 24984–24992
15. Marcus, N. Y., Marcus, R. A., Schmidt, B. Z., and Haslam, D. B. (2007) *Arch. Biochem. Biophys.* **468**, 147–158
16. Jin, Y., Zhuang, M., and Hendershot, L. M. (2009) *Biochemistry* **48**, 41–49
17. Haraga, A., and Miller, S. I. (2003) *Infect Immun* **71**, 4052–4058
18. Nakanishi, K., Kamiguchi, K., Torigoe, T., Nabeta, C., Hirohashi, Y., Asanuma, H., Tobioka, H., Koge, N., Harada, O., Tamura, Y., Nagano, H., Yano, S., Chiba, S., Matsumoto, H., and Sato, N. (2004) *Cell Stress Chaperones* **9**, 253–264
19. Martoglio, B., and Dobberstein, B. (1998) *Trends Cell Biol.* **8**, 410–415
20. Bies, C., Guth, S., Janoschek, K., Nastainczyk, W., Volkmer, J., and Zimmermann, R. (1999) *Biol. Chem.* **380**, 1175–1182
21. Meunier, L., Usherwood, Y. K., Chung, K. T., and Hendershot, L. M. (2002) *Mol. Biol. Cell* **13**, 4456–4469
22. Shen, Y., and Hendershot, L. M. (2005) *Mol. Biol. Cell* **16**, 40–50
23. Yu, M., and Haslam, D. B. (2005) *Infect. Immun.* **73**, 2524–2532
24. Bendtsen, J. D., Nielsen, H., von Heijne, G., and Brunak, S. (2004) *J. Mol. Biol.* **340**, 783–795
25. Kang, S. W., Rane, N. S., Kim, S. J., Garrison, J. L., Taunton, J., and Hegde, R. S. (2006) *Cell* **127**, 999–1013
26. Kim, S. J., Mitra, D., Salerno, J. R., and Hegde, R. S. (2002) *Dev. Cell* **2**, 207–217
27. Johnson, S., Michalak, M., Opas, M., and Eggleton, P. (2001) *Trends Cell Biol.* **11**, 122–129
28. Cheetham, M. E., and Caplan, A. J. (1998) *Cell Stress Chaperones* **3**, 28–36
29. Fan, C. Y., Lee, S., and Cyr, D. M. (2003) *Cell Stress Chaperones* **8**, 309–316
30. Li, J., Qian, X., and Sha, B. (2003) *Structure* **11**, 1475–1483
31. Li, J., and Sha, B. (2005) *Biochem. J.* **386**, 453–460
32. Malhotra, J. D., and Kaufman, R. J. (2007) *Semin Cell Dev. Biol.* **18**, 716–731
33. Collier-Hyams, L. S., Zeng, H., Sun, J., Tomlinson, A. D., Bao, Z. Q., Chen, H., Madara, J. L., Orth, K., and Neish, A. S. (2002) *J. Immunol.* **169**, 2846–2850
34. Fink, S. L., and Cookson, B. T. (2007) *Cell Microbiol.* **9**, 2562–2570
35. Kim, J. M., Eckmann, L., Savidge, T. C., Lowe, D. C., Witthöft, T., and Kagnoff, M. F. (1998) *J. Clin. Invest.* **102**, 1815–1823
36. Cheminay, C., Möhlenbrink, A., and Hensel, M. (2005) *J. Immunol.* **174**, 2892–2899
37. Tobar, J. A., Carreño, L. J., Bueno, S. M., González, P. A., Mora, J. E., Quezada, S. A., and Kalergis, A. M. (2006) *Infect. Immun.* **74**, 6438–6448
38. Halici, S., Zenk, S. F., Jantsch, J., and Hensel, M. (2008) *Infect. Immun.* **76**, 4924–4933
39. Granados, D. P., Tanguay, P. L., Hardy, M. P., Caron, E., de Verteuil, D., Meloche, S., and Perreault, C. (2009) *BMC Immunol.* **10**, 10
40. Hanahan, D. (1983) *J. Mol. Biol.* **166**, 557–580
41. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) *Cell* **75**, 805–816